Literature DB >> 7296492

The transport and accumulation of methotrexate in human erythrocytes.

M da Costa, M P Iqbal.   

Abstract

The uptake of methotrexate (MTX) by human erythrocytes was studied in vivo and in vitro. Following a pulse intravenous injection of MTX in two subjects, MTX accumulated rapidly in erythrocytes and its intracellular concentration declined at a slower rate than the serum concentration. Twenty-four hours later erythrocytes had no MTX but the drug reappeared 3-7 days later. In subjects receiving twice monthly MTX, the drug accumulated in the erythrocytes as protein-bound (61%) and nonprotein bound (39%) forms. The latter is presumably MTX-polyglutamate. In vitro, MTX uptake by erythrocytes was virtually absent at plasma concentrations of 1 nM-1 micro M, but uptake increased substantially above 10 micro M by a mechanism which was not saturated even at 1 mM. The major fraction of MTX which accumulated by erythrocytes in vitro effluxed during the first minute and was not protein-bound, unlike MTX which accumulated in vivo. This suggests that MTX binds to a protein in developing erythroblasts which contain dihydrofolate reductase and that the delayed appearance of MTX in circulating erythrocytes following in vivo administration corresponds to bone marrow maturation time of erythroblasts.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7296492     DOI: 10.1002/1097-0142(19811201)48:11<2427::aid-cncr2820481115>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Pharmacokinetics of methotrexate in erythrocytes in psoriasis.

Authors:  J Hendel; A Nyfors
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

2.  Methotrexate metabolism.

Authors:  G R Krakower; B A Kamen
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Wanda L Salzer; Naomi J Winick; Pierre Wacker; Xiaomin Lu; Meenakshi Devidas; Jonathan J Shuster; Donald H Mahoney; Stephen J Lauer; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2012-01       Impact factor: 1.289

4.  A pteroylpolyglutamate binds to tetramers in deoxyhemoglobin but to dimers in oxyhemoglobin.

Authors:  R E Benesch; R Benesch; S Kwong; C M Baugh
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

5.  Influence of high-dose methotrexate on the distribution of body fluid volumes in the dog.

Authors:  S S de Graaf; J A de Vries; W G Zijlstra
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis.

Authors:  Jaroslav Chládek; Marie Simková; Jaroslava Vanecková; Milos Hroch; Jirina Chládkova; Jirina Martínková; Jaroslava Vávrová; Martin Beránek
Journal:  Eur J Clin Pharmacol       Date:  2007-12-29       Impact factor: 2.953

7.  Methotrexate in neutrophils in children with acute lymphoblastic leukemia.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  The accumulation of mercaptopurine metabolites in age fractionated red blood cells.

Authors:  A Rostami-Hodjegan; L Lennard; J S Lilleyman
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

9.  Methotrexate pharmacokinetics in age-fractionated erythrocytes.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study.

Authors:  M L Graham; J J Shuster; B A Kamen; D L Cheo; M P Harrison; B G Leventhal; D J Pullen; V M Whitehead
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.